## ELV: Elevance Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.7% below STRENGTH zone (3.0-6.0%); PEG 1.01 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($335.13)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Generate Investment Management Ltd Has $43.62 Million Holdings in Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251231T114440 | Somewhat-Bullish | Relevance: 100%
- Generate Investment Management Ltd significantly increased its stake in Elevance Health, Inc. (NYSE:ELV) by 37.7% during the third quarter, bringing its total holdings to 135,000 shares valued at $43.62 million. This move positions Elevance Health as the 10th largest holding in Generate Investment Management Ltd's portfolio. Other institutional investors have also adjusted their positions, and analysts have issued varied ratings, with a consensus "Hold" and an average target price of $396.21.

**2. Brookstone Capital Management Sells 8,259 Shares of Elevance Health, Inc. $ELV**
- Source: MarketBeat | 20251231T090609 | Somewhat-Bullish | Relevance: 100%
- Brookstone Capital Management significantly reduced its stake in Elevance Health (NYSE:ELV) by 80.2%, selling 8,259 shares but retaining 2,040 shares valued at $659,000. Elevance Health exceeded Q3 expectations with EPS of $6.03 and revenues of $50.09 billion, while also declaring a quarterly dividend of $1.71. Analysts currently maintain a "Hold" rating for the stock with an average price target of $396.21.

**3. What Do Analysts Think About Elevance Health (ELV)?**
- Source: Finviz | 20251230T070804 | Neutral | Relevance: 100%
- Deutsche Bank analyst George Hill downgraded Elevance Health (ELV) to Hold and reduced its price target to $320 from $332 on December 19, whereas BofA increased its price target to $385 from $370 on December 16, reaffirming a Neutral rating. Elevance Health also announced the appointment of Amy Schulman as an independent director, effective January 12, 2026, and expanded access to its Virtual Assistant digital experience. The company operates through several segments including Health Benefits, CarelonRx, and Carelon Services.

**4. UNH vs. ELV: Which Managed Care Stock Has the Edge Today?**
- Source: The Globe and Mail | 20251230T182848 | Somewhat-Bullish | Relevance: 100%
- This article compares UnitedHealth Group (UNH) and Elevance Health (ELV), two major players in the U.S. managed healthcare sector. While UNH, the largest insurer, benefits from its diversified Optum segment, it faces challenges from rising medical costs and regulatory scrutiny. ELV, despite also facing cost pressures, presents a stronger near-term risk-reward profile due to strategic exits from underperforming markets, the growth of its Carelon platform, and a more appealing valuation.

**5. UNH vs. ELV: Which Managed Care Stock Has the Edge Today?**
- Source: The Globe and Mail | 20251230T122600 | Somewhat-Bullish | Relevance: 100%
- UnitedHealth Group (UNH) and Elevance Health, Inc. (ELV) are major players in the U.S. managed healthcare market, both facing increased medical costs and regulatory scrutiny. While UNH boasts significant scale and its diversified Optum segment, it confronts regulatory investigations and short-term margin pressures. ELV, with its growing Carelon platform and strategic market exits, appears to offer a stronger near-term risk-reward outlook due to its more attractive valuation and recent outperformance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-19 | Deutsche Bank | $320 | $332 | -4% |
| 2025-12-18 | Morgan Stanley | $352 | $359 | -2% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-19 | Deutsche Bank | down | Hold |
| 2025-12-18 | Morgan Stanley | main | Equal-Weight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.3% (+0.6%)
- Blackrock Inc.: 9.2% (+0.6%)
- State Street Corpora: 4.7% (-2.1%)
- Wellington Managemen: 3.0% (+4.8%)
- Price (T.Rowe) Assoc: 2.6% (-27.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +4.9% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Analyst sentiment negative (2 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $78.9B |
| Beta | 0.53 |
| 52W Range | $273.71 - $458.75 |
| Short Interest | 2.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 13.1 |
| Current P/E | 11.7 |
| YoY Growth | -10.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.2% to 1.7% (+4.9% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.3pp (needs >3.0% for momentum thesis). MRS_5 at 1.6% confirms short-term momentum alignment. Below SMA200 (0.99x), long-term trend not supportive. RSI neutral at 59. OFD pattern: +MUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.70% (CS: 94) | Neutral |
| RSI_14 | 58.7 | Neutral |
| MACD Histogram | -0.12 | Bearish |
| vs SMA20 | 1.018x | Above |
| vs SMA50 | 1.048x | Above |
| vs SMA200 | 0.990x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $350.49
- **Stop Loss:** $335.13 (4.4% risk)
- **Target:** $365.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 93
- **Position Value:** $32,595.57
- **Portfolio %:** 32.60%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-01-22 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.94 | $6.03 | +22.0% |
| 2025Q2 | $8.96 | $8.84 | -1.4% |
| 2025Q1 | $11.48 | $11.97 | +4.3% |
| 2024Q4 | $3.85 | $3.84 | -0.3% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*